Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery

https://doi.org/10.1016/0168-3659(95)00147-6Get rights and content

Abstract

Poor oral bioavailability for many drugs is generally attributed to poor solubility in the gastrointestinal fluids, poor gut membrane permeability and/or extensive hepatic first-pass elimination. Recently, however, it has been recognized that cytochrome P-450 3A mediated drug metabolism in the intestine, and P-glycoprotein counter-transport processes may also contribute significantly to poor drug bioavailability. We have shown that cyclosporin, a highly lipid soluble, large molecular weight compound does not appear to have absorption problems, with approximately 86% of the present commercial formulation being absorbed intact in healthy volunteers. Rather, the low bioavailability of cyclosporin results from extensive metabolic extraction in the gut which approaches 60%. Recently, a strong overlap has been identified between substrates for gut metabolism by cytochrome P-450 3A and gut counter-transport by P-glycoprotein, suggesting that these processes may work together to limit the bioavailability of a large number of drug substances. Recognition of this potential for metabolism and counter-transport process in the gut leads to a new perspective on improving drug bioavailability that differs from the traditional physico-chemical approach.

References (12)

  • J.C. Kolars et al.

    First-pass metabolism of cyclosporin by the gut

    Lancet

    (1991)
  • B. Hoener et al.

    Factors influencing drug absorption and drug availability

  • M. Rowland et al.

    Clinical Pharmacokinetics: Concepts and Applications

  • Y.K. Tam

    Individual variation in first-pass metabolism

    Clin. Pharmacokinet.

    (1993)
  • F. Thiebaut et al.

    Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

  • P.B. Watkins et al.

    Identification of glucocorticoid-inducible cytochromes P-450 in intestinal mucosa of rats and man

    J. Clin. Invest.

    (1987)
There are more references available in the full text version of this article.

Cited by (189)

  • Quantitative Assessment of the Impact of Crohn's Disease on Protein Abundance of Human Intestinal Drug-Metabolising Enzymes and Transporters

    2022, Journal of Pharmaceutical Sciences
    Citation Excerpt :

    Verapamil bioavailability increased by two fold while no change was observed with digoxin and rosuvastatin. Drugs that are substrates of more than one protein, especially those suggested to work in synergy, such as CYP3A4 and P-gp,82–84 are expected to incur higher changes in bioavailability.85–88 Limitations of this study include the use of pooled samples, which does not afford a measure of variability between patients.

  • Microfluidic Organ-on-a-Chip Models of Human Intestine

    2018, Cellular and Molecular Gastroenterology and Hepatology
View all citing articles on Scopus
View full text